On Wednesday, the FTSE 100 experienced a slight decline, breaking its streak after 16 consecutive sessions of gains. Investor confidence was dampened due to significant losses in the pharmaceutical sector, notably with AstraZeneca and GSK, which fell by nearly 2.5% and more than 4%, respectively. This decline came following negative reactions in US markets to Vinay Prasad's recent appointment. Despite some encouraging corporate updates, overall market sentiment was mixed. BAE Systems maintained its optimistic outlook, spurred by strong global demand for defense, while Trainline reported profits that exceeded expectations.
In terms of policy developments, UK and US officials are engaged in intensive negotiations to forge a new economic agreement aimed at alleviating tariffs, prompting optimism for reduced trade tensions. This follows the UK's significant trade pact with India, its largest post-Brexit agreement. Meanwhile, the global markets are observing cautiously as US-China trade discussions recommence in Switzerland, a strategic move intended to ease ongoing tensions affecting the global economic landscape.
